U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07121205) titled 'High-Dose Dual Therapy for H. Pylori Eradication (RETRO-HP Study)' on Aug. 04.
Brief Summary: Background:
High-dose dual therapy (HDDT) has emerged as a potential first-line treatment for Helicobacter pylori infection, but its efficacy and safety across different regimens and populations remain unclear. This study aimed to compare real-world outcomes of various HDDT protocols and identify factors influencing treatment failure.
Methods:
A multicenter retrospective analysis was conducted using data from 15 medical centers (January 2022-January 2025). Patients received one of four HDDT regimens: vonoprazan-amoxicillin for 10 days (V...